IO170 / IO Biotech - LARVOL DELTA

A TGFβ-directed immune-modulatory vaccine induces T cell activation and drives antitumor activity by modulating the tumor microenvironment (AACR 2025) - "Currently, to clarify the mechanism of action, we are implementing the 4T1 model of mammary carcinogenesis to model metastatic disease and exploring spatial relationships to identify which cell types and tissue architectures are pivotal for meaningful responses.In conclusion, our data indicate the efficacy of TGFβ peptide vaccine in eliciting an immune response and tumor growth inhibition in mouse models of cancer. These observations warrant further preclinical investigation to better understand the efficacy and the safety profile of this novel TGFβ-targeting strategy."

Biomarker • Tumor microenvironment • Breast Cancer • Genito-urinary Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Prostate Cancer • Solid Tumor • CD8 • TGFB1

Pre-clinical data from IO170, IO Biotech’s third therapeutic cancer vaccine candidate derived from the company’s T-win platform, also presented at SITC 2025 (GlobeNewswire) - "The data presented in this poster showcase an alternative approach, where TGF-β-specific T cells are activated through a peptide vaccination to target TGF-β-expressing cells to promote anti-tumor activities in a cancer model."

Preclinical • Solid Tumor

A TGFβ-directed immune-modulatory vaccine leads to T cell activation, tumor growth inhibition and reduces metastases (SITC 2025) - "Finally, the metastatic dissemination to the lungs was reduced by 35% compared to control mice.Conclusions Our data indicated the activity of TGF-β peptide vaccine in eliciting an immune response in both human (in vitro) and mouse (in vivo) which could inhibit tumor growth and reduced lung metastasis in a murine model of cancer. These observations warrant further preclinical investigation to better understand the activity and the safety profile of this novel TGFβ-targeting strategy."

Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • IFNG • TGFB1

IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170 (GlobeNewswire) - "Poster Highlights: IO102-IO103, a dual-antigen vaccine targeting IDO1+ and PD-L1+ cells, generated strong T-cell responses and modulated the tumor microenvironment in two mouse models, where IDO1 and PD-L1 vaccine each contributed differently to control tumor growth. Gene expression profiling also showed that the vaccine triggered unique molecular changes not seen with PD-1 or PD-L1 inhibitors, indicating a potentially synergistic mechanism. (Abstract #2241); IO170, also developed using IO Biotech’s T-win platform, demonstrated significant tumor growth inhibition in breast and prostate cancer mouse models. The TGF- β-directed vaccine led to infiltration of vaccine-specific T cells with increased density of CD8+ T-cells in the tumor and reshaped the tumor microenvironment to favor immune activation. Spatial analysis in prostate tumors showed increased cytotoxic immune regions and reduced levels of suppressive cells like M2 macrophages. (Abstract #2257)."

Preclinical • Breast Cancer • Prostate Cancer

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) - "IO Biotech...announced that two abstracts have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025....New non-clinical data strengthens evidence of contributions of IO102 and IO103 to tumor growth control through target specific T-cell activation, offering a distinct and complementary approach to checkpoint inhibitors. New preclinical data for IO170 add to growing body of evidence supporting the potential of immune-modulatory therapeutic cancer vaccines to treat a wide range of cancers."

Preclinical • Solid Tumor

IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference (GlobeNewswire) - "IO Biotech...announced details of its poster presentation at the American Association for Cancer Research (AACR)-IO conference taking place February 23-26, 2025....The poster details the potential of IO170, a TGF-β peptide vaccine that showed significantly reduced tumor growth in pancreatic adenocarcinoma and prostate cancer models. The vaccine-induced robust immune responses reshaped the TME without causing systemic toxicity or adverse off-target effects. These findings support the continued development of an immune-modulatory vaccine targeting TGF-β as a novel approach for treating a wide range of cancers....'We look forward to advancing this research and sharing additional data as we explore its clinical applications while we prepare for an Investigational New Drug Application (IND) submission to FDA for IO170'."

Preclinical • Pancreatic Adenocarcinoma • Prostate Cancer